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Abstract 
BACKGROUND: Hypertension (HTN) is the most prevalent non-infectious disease worldwide 
and can lead to mortality. This trial aimed to compare the effect of N-acetylcysteine (NAC) and 
angiotensin-converting enzyme inhibitors (ACEIs) on controlling blood pressure in hypertensive 
patients. 
METHODS: This cross-sectional clinical trial was conducted in Hajar Hospital, Shahrekord, Iran, 
in 2009. A sample of 126 patients with HTN was selected and randomly divided into 2 groups 
(group A and group B). First, group A was treated with ACEI alone and group B with ACEI + 
NAC for 2 months. Blood pressure of all patients was evaluated each week. After a 2 week period 
of washout, the drugs were changed. In the second period of the trial, group A was treated with 
ACEI + NAC and group B with NAC alone and their blood pressure was evaluated in the same 
manner as the previous period. The data were analyzed using SPSS. 
RESULTS: A significant reduction was observed in systolic and diastolic blood pressure of 
patients (P < 0.050). However, during both periods of the trial, the group receiving NAC + ACEI 
experienced a more significant reduction in blood pressure compared with the ACEI group  
(P < 0.050). 
CONCLUSION: NAC accompanied with ACEI decreased the patients’ systolic and diastolic blood 
pressure significantly; however, ACEI alone did not have any significant effects on blood 
pressure. Systolic blood pressure decreased 7 mmHg on average and fluctuated during the trial. 
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Introduction 
Hypertension (HTN) (high blood pressure) is a risk 
factor which leads to renal failure, peripheral 
vascular disease, retinopathy, stroke, and heart 
attacks.1,2 Some research studies have indicated that 
oxidative stress and reactive oxygen species 
participate in the pathogenesis of cardiovascular 
diseases, including HTN and atherosclerosis.3,4 
The relevant literature indicates the stability of 
or decrease in HTN prevalence in developed 
countries and increase in its prevalence in 
developing countries. In addition, no significant 
cross-sectional association was observed between 
developed and developing countries regarding the 
prevalence of awareness, treatment, and control of 
HTN. The mean level among men in developed 
countries was higher than that in developing 
countries. Prevalence of HTN varies worldwide, 
with the lowest prevalence in rural India (3.4% in 
men and 6.8% in women) and the highest 
prevalence in Poland (68.9% in men and 72.5% in 
women).5,6 
The purpose of treating this disease is to regulate 
blood pressure; lower than 140/90 in healthy 
individuals and lower than 130/85 in patients 
suffering from diabetes or kidney disease. In most 
cases, HTN treatment has various side-effects, and 
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administration of a drug that is effective in reducing 
cardiovascular disease risk factors (decrease in 
cholesterol, homocysteine, and plasma lipoprotein a, 
and increase in high-density lipoprotein) will lead to 
the progress of HTN treatments and increase of 
these patients’ prognosis. According to the 
investigations conducted on anti-HTN drugs, 
angiotensin-converting enzyme inhibitors (ACEIs) 
are the first choice in treating HTN. These drugs 
are useful especially in patients with kidney HTN, 
renovascular HTN, diabetes, as well as accelerated 
and malignant HTN. In mild and uncomplicated 
HTN, these drugs are as effective as beta-blockers 
and thiazides. Individuals afflicted with bilateral 
artery stenosis also suffer from acute renal failure.7,8 
Several lines of evidence have shown the 
antihypertensive role of cysteine. Some reports 
using dietary supplementation of the cysteine analog 
N-acetylcysteine (NAC) have indicated that it 
prevents or attenuates increased blood pressure in 
animal models of HTN.9-20 It has also been 
demonstrated that the cysteine precursor 
methionine results in increasing of the 
cardiovascular risk factor and homocysteine results 
in increasing of blood pressure in normal rats.21-23 
Homocysteine has been shown to lower blood 
pressure in hypertensive rats.24,25 In addition, in 
human studies, using NAC as an adjunct to other 
antihypertensive therapies resulted in a decrease in 
blood pressure.26,27 
No research has been performed using NAC as a 
monotherapy in humans suffering from HTN. 
However, in a study including six hypertensive 
participants with good blood pressure control (mean: 
139/93 mmHg) with the ACE inhibitor lisinopril, the 
increasing of NAC by 1.2 g/day for 1 week resulted in 
a significant decrease in both systolic and diastolic 
blood pressure.28 In another study, the participants 
consisted of 18 hypertensive smokers whose blood 
pressure was not controlled with ACE inhibitor 
monotherapy (enalapril or captopril). These 
participants received 1.8 g/day NAC for 21 days. This 
treatment resulted in a decrease in 24 hour ambulatory 
and daytime systolic and diastolic blood pressure.29 
Another study assessed the influence of a combination 
of equal doses of NAC and arginine [the substrate of 
nitric oxide (NO) synthase], 1.2 g/day, in a group of 
12 type 2 diabetic patients with HTN.30 
One of the pathophysiologic mechanisms 
suggested in HTN is reduction in the vasodilating 
factor derived from endothelial cell (such as NO). 
Moreover, NAC, as an antioxidant, causes an 
increase in NO derived from endothelial cells due 
to its mechanism on NO. NAC can decrease 
homocysteine and lipoprotein and protect the heart 
against ischemic and perfusion damages on the 
myocytes through replenishing group of sulfhydryl. 
Its other effects are increasing the nitroglycerin 
activity, doubling the anti-platelet effect, dilating 
coronary veins, and reducing the ratio of tolerance 
to the hemodynamic effects of nitroglycerine.27,28,31 
Considering the abovementioned effects, this drug 
can lead to blood pressure reduction. Many studies 
examining the effect of NAC (based on the 
mechanism dependent on NO) in combination with 
ACEI in patients with HTN have shown 
contradictory results.29,32 Due to the daily increase in 
the worldwide death toll due to HTN, and some 
damages due to this disease, which affect the whole 
society, and because no research similar to the 
present one existed in Iran or worldwide, this 
clinical trial was conducted to compare the effect of 
NAC and ACEIs on controlling blood pressure in 
hypertensive patients. 
Materials and Methods 
This clinical trial with ethics code 89-2-1 was 
conducted in Hajar Hospital in Shahrekord, Iran, in 
2009-2010. The population studied included all 
patients of 18 years and older with HTN referring 
to this hospital. The inclusion criteria consisted of 
age above 18 years, systolic blood pressure of 140 
mmHg or higher, diastolic blood pressure of 90 
mmHg or higher in spite of taking ACEI, isolated 
systolic or diastolic HTNs, and diagnosis of HTN 
by a cardiologist. In addition, patients with HTN 
who took ACEI (enalapril or captopril) with doses 
determined by the respective physician and not 
changed during the trial, and did not take any other 
antihypertensive drugs, were also allowed to enter 
the study. Individuals with cystinuria, kidney stones, 
especially cysteine stones, and severe sensitivity to 
ACEI and NAC (such as coughing, digestive 
disorder, and etc.), and also patients who needed 
other antihypertensive drugs besides ACEI to 
control their blood pressure were excluded from the 
trial. 
The sampling method was based on convenience 
sampling. The sample size was calculated based on a 
95% confidence and a power of 80% to see a 
difference equal to 50% of standard deviation in the 
mean of blood pressure between two groups. The 
estimated sample size was 126 patients (63 patients 
in each group). At the beginning of the study, a 
consent form was filled by the patients and the 
ethical principles were taken into consideration. 
Finally, 126 patients with HTN were entered 
into the study, and then, randomly divided into two 
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groups (A and B). ACEI alone was administered to 
group A and NAC tablets with the doses of 600 
mg/12 hours in combination with ACEI was 
prescribed for 2 months for group B. In addition, 
NAC treating dose did not change during the trial. 
During these 2 months, blood pressures of both 
groups were measured every 5-7 days in the clinic. 
After this period, none of the two groups received 
NAC for 2 weeks and only received ACEI (washout 
period). Then, the two groups’ programs were 
exchanged, and hence, for 2 months the group that 
received NAC+ACEI received ACEI alone and the 
group that received ACEI alone received NAC and 
ACEI. Subsequently, similar to the previous 2-
month period, the blood pressure (systolic and 
diastolic) of all patients was measured by two 
observers every 5-7 days using the same manometer 
(Riester, Jungingen, Germany) and stethoscope 
(Welch Allyn, Tycos Instruments Inc., Skaneateles 
Falls, NY, USA) in the clinic. Finally, the results 
were reported as the mean decrease in blood 
pressure. Every equipment in this study was 
calibrated once a month. 
Data collection was conducted using the 
questionnaire and measuring the patients’ blood 
pressures. The questionnaire asked about the 
patients’ age, gender, place of residence, duration of 
HTN history, antihypertensive drugs (enalapril or 
captopril), and duration of drug taking, blood 
pressure, diabetes, and smoking (Figure 1). 
 
 
Figure 1: Number of subjects involved at each stage of the study (Flowchart) 
 
Total number of hypertensive patients 
screened (n = 126)
Not randomized (n = 0) Randomized into two groups
Study group
A: Received NAC+ACEI (n = 63)
B: Received ACEI (n = 63)
Follow-up (measurment of  blood 
pressure once each 5 to 7 days)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analysis
Group B (n = 63)
Excluded from analysis 
(n = 0)
Group A (n = 63)
Excluded from analysis (n = 0)
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For continuous variables, data were presented as 
means ± standard deviation (SD) and for categorical 
variables, as number with frequency. Because the 
sample size was moderately high in each group, the 
parametric test was used. A repeated measures 
analysis of variance (ANOVA) was used to compare 
the blood pressures of the two groups. The 
multivariate F-tests of Greenhouse-Geisser were 
used within the subject analysis because of the 
violation in sphericity assumptions. The comparisons 
of other variables of interest between the two groups 
were made using the chi-square or Fisher’s exact test 
for categorical variables and independent t-test for 
continuous variables. Statistical analysis was 
performed using SPSS (version 11.5, SPSS Inc., 
Chicago, IL, USA). All P values below 0.050 were 
considered statistically significant. 
Results 
There were 65 patients in each group at the 
beginning of the study, 4 of whom from group A 
were excluded due to not referring or following the 
treatment. Therefore, 61 and 65 individuals 
continued drug-taking until the completion of the 
study in the first and second groups, respectively. 
The mean (± SD) of age in groups A and B were 
58.9 ± 12.4 and 57.1 ± 9 years, respectively, with no 
significant difference between the two groups  
(P = 0.340). Among all studied patients, 42 and 84 
individuals (33.3 vs. 66.7%) were male and female, 
respectively. There were 17 and 25 men in groups A 
and B (27.9 vs. 38.5%), respectively. Furthermore, 
there was no significant difference between the two 
groups in terms of gender (P = 0.210). Out of the 
126 patients studied, 22(17.5%) had diabetes, 9 and 
13 (14.8 vs. 20%) of whom were in groups A and B, 
respectively. In addition, 6 patients smoked, 2 and 4 
of whom were in groups A and B, respectively. 
Moreover, 25 and 32 participants (41 vs. 49.2%) of 
groups A and B, respectively, took Enalapril. There 
was no significant difference in the frequency of 
diabetes, smoking, and the type of drug taken 
between the two groups (P > 0.050). 
The mean systolic blood pressure during the 
study is shown in table 1 and the mean diastolic 
blood pressure in table 2. Furthermore, the trend of 
systolic and diastolic blood pressures of the two 
groups for the two periods is illustrated in figures 2 
and 3, respectively. 
No difference was observed in the mean systolic 
and diastolic blood pressure at the beginning of the 
study. The comparison of mean systolic and 
diastolic blood pressures during the study showed 
that the blood pressure of the group receiving NAC 
+ ACEI (group A) was lower than the group 
receiving ACEI (group B). Based on the repeated 
measure analysis of variance, a significant reduction 
trend exists in systolic and diastolic blood  
 
Table 1. Mean and standard deviation (SD) of systolic blood pressure in the two groups 
Time Group time A B P Mean ± SD Mean ± SD 
The first 2 month 
Beginning of the study 12.0 ± 156.1 12.1 ± 157.2 0.610 
At the end of 1st week 10.0 ± 150.9 14.0 ± 147.9 0.170 
At the end of 2 week 10.2 ± 151.9 13.6 ± 145.3 0.003 
At the end of 3 week 10.6 ± 151.6 14.3 ± 142.1 < 0.001 
At the end of 4 week 10.5 ± 149.0 12.1 ± 140.4 < 0.001 
At the end of 5 week 8.7 ± 150.7 10.9 ± 138.8 < 0.001 
At the end of 6 week 10.4 ± 151.6 13.3 ± 138.2 < 0.001 
At the end of 7 week 9.0 ± 148.7 12.0 ± 137.4 < 0.001 
At the end of 8 week 10.1 ± 152.0 11.5 ± 138.7 < 0.001 
The second 2 month 
At the initiation to inter the 
second treatment month 8.8 ± 149.2 9.9 ± 152.6 0.420 
At the end of 1st week 10.1 ± 143.0 12.4 ± 151.7 < 0.001 
At the end of 2 week 11.0 ± 141.0 12.5 ± 150.8 < 0.001 
At the end of 3 week 10.0 ± 137.9 11 ± 150.3 < 0.001 
At the end of 4 week 11.0 ± 138.7 11.5 ± 149.9 < 0.001 
At the end of 5 week 9.6 ± 138.3 12.2 ± 151.1 < 0.001 
At the end of 6 week 10.3 ± 138.5 12.3 ± 151.7 < 0.001 
At the end of 7 week 8.7 ± 137.0 11.3 ± 149.5 < 0.001 
At the end of 8 week 9.7 ± 4139.4 10.2 ± 151.3 < 0.001 
Group A: the first treatment 2 months with ACEI alone and the second with NAC + ACEI; Group B: the first treatment 2 months 
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Table 2. Mean and standard deviation (SD) of diastolic blood pressure in the two groups 
Time Group time A B P Mean ± SD Mean ± SD 
The first 2 month 
Beginning of the study 9.8 ± 100.5 18.3 ± 96.8 0.170 
At the end of 1st week 8.6 ± 96.9 10.0 ± 92.2 < 0.005 
At the end of 2 week 9.5 ± 96.4 10.6 ± 89.7 < 0.001 
At the end of 3 week 9.0 ± 96.7 10.4 ± 86.8 < 0.001 
At the end of 4 week 9.6 ± 94.9 8.8 ± 85.5 < 0.001 
At the end of 5 week 7.7 ± 96.1 8.0 ± 84.5 < 0.001 
At the end of 6 week 9.2 ± 97.5 10.2 ± 84.4 < 0.001 
At the end of 7 week 8.2 ± 94.4 7.7 ± 82.6 < 0.001 
At the end of 8 week 8.3 ± 97.4 8.0 ± 38.8 < 0.001 
The second 2 month 
At the initiation to inter the 
second treatment month 7.4 ± 95.4 8.3 ± 86.3 0.520 
At the end of 1st week 9.4 ± 91.1 10.1 ± 95.3 0.016 
At the end of 2 week 10.0 ± 87.7 10.0 ± 94.5 0.001 
At the end of 3 week 8.7 ± 85.4 8.7 ± 94.3 < 0.001 
At the end of 4 week 10.0 ± 86.1 13.8 ± 92.8 < 0.001 
At the end of 5 week 8.8 ± 86.1 9.0 ± 94.7 < 0.001 
At the end of 6 week 6.8 ± 85.4 9.9 ± 94.8 < 0.001 
At the end of 7 week 7.8 ± 85.2 8.5 ± 93.6 < 0.001 
At the end of 8 week 8.0 ± 84.5 7.3 ± 95.0 < 0.001 
Group A: the first treatment 2 months with ACEI alone and the second with NAC + ACEI; Group B: the first treatment 2 months 




Figure 2. The mean trend of systolic blood pressure in the two groups [Group A: the first 2 months of 
treatment with angiotensin converting enzyme inhibitors (ACEI) alone and the second  with N-
acetylcysteine (NAC) + ACEI; Group B: the first 2 months of treatment with NAC + ACEI and the 
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Figure 3. The mean trend of diastolic blood pressure in the two groups [Group A: The first 2 months of 
treatment with angiotensin converting enzyme inhibitors (ACEI) alone and the second with N-
acetylcysteine (NAC) + ACEI; Group B: The first 2 months of treatment with NAC + ACEI and the 
second with ACEI alone] 
 
Table 3. The result of repeated measure analysis of variance for the blood pressures factor 
Blood pressure Period Source of variation df F P 
Systolic 
First 
Time 6.76 44.4 < 0.001 
Time × group 6.76 16.0 < 0.001 
Error 838   
Second 
Time 6.88 14.2 < 0.001 
Time × group 6.88 7.2 < 0.001 
Error 853   
Diastolic 
First 
Time 5.08 26.1 < 0.001 
Time × group 5.08 9.3 < 0.001 
Error 630   
Second 
Time 6.06 14.6 < 0.001 
Time × group 6.06 6.9 < 0.001 
Error 752.00   
Df: Degree of freedom 
 
pressures of patients during the study in the two 
periods (P < 0.050). However, during the two 
periods, group A had a more significant reduction 
in systolic and diastolic blood pressures compared 
to group B (P < 0.050). Furthermore, the result of 
repeated measure ANOVA for the blood pressures 
is shown in table 3. 
Discussion 
The purpose of this study was to compare the 
effects of NAC (group A) plus ACEIs with ACEIs 
alone (group B) in controlling the patients’ blood 
pressure. Based on the obtained results, NAC 
accompanied with ACEIs can decrease the patients' 
systolic and diastolic blood pressure (group A) 
significantly. However, ACEIs (group B) did not 
have any significant effects on their blood pressures. 
Systolic blood pressure decreased 7 mmHg on 
average, and fluctuated during the study. It is 
ACEIs accompanied with NAC that can have a 
quite significant effect on the reduction trend of the 
patients’ systolic blood pressure. Systolic blood 
pressure reduction in these patients was 18.5 mmHg 
on average; in other words, taking NAC could 
decrease the patients’ systolic blood pressures by 
more than two times. In addition, the rate of 
diastolic blood pressure reduction in patients who 
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mmHg on average, while the group A patients’ 
blood pressures reduced by 13 mmHg on average. 
On the other hand, the fluctuations of diastolic 
blood pressure in these patients were less than the 
patients who used ACEI alone (group B). 
Regarding the effect of NAC on blood pressure, 
there have so far been numerous studies on animals, 
most of which have obtained positive results 
regarding the reduction of blood pressure. In the 
study conducted by Barrios et al., the heart ward of 
Madrid Ramony Cajal Hospital, NAC was presented 
as a receptor of the sulfhydryl group which can 
strengthen the antihypertensive effect of the drugs 
acting through NO mechanism. The studied 
participants with HTN who smoked consisted of 15 
men and 3 women with the mean age of 69 ± 5 
years. A considerable reduction (about 7%) was 
observed in the daily and 24 hour systolic and 
diastolic blood pressure of patients who took NAC 
accompanied with ACEI, comparable with ACEI 
alone. According to the mentioned studies, adding 
NAC to ACEI strengthens their antihypertensive 
effects in smoking patients with HTN. This effect 
can be dependent on NO mechanism and NAC 
causes an increase in it through the protective effect 
from NO oxidation.28 In another study conducted 
by Bernatova et al., it was concluded that in the 
blood pressure dependent on NO shortage, the 
patients will improve more significantly through 
treatment by antioxidants due to the increase in NO 
production.31 In the study by Ruiz et al., NAC was 
presented as a sulfhydryl group giver which 
automatically strengthened the reaction to captopril 
and enalapril treatment in rabbits with hypertension, 
and this effect was implemented by the mechanism 
dependent on NO and NAC-increased level of 
NO.11 In the study by Martina et al. the decrease in 
systolic blood pressure was associated with type 2 
diabetes in hypertensive patients.29 Pharmacological 
analysis of the underlying mechanisms indicated 
voltage-gated potassium channels engagement in 
vasodilatory effect of NAC.32 In another study, 
NAC was shown to prevent HTN, insulin 
resistance, and oxidative stress in rats chronically 
fed with glucose.33 Renke et al. reported that the 
effect of NAC on kidney function, kidney damages, 
and blood pressure in HTN sensitive to salt was 
examined. In this study, 44 rabbits of 7-8 weeks of 
age that received high doses of sodium for 5 weeks 
underwent treatment by NAC with the dose of 4 
g/kg/day. While mean arterial pressure had gone up 
to 1183 mm Hg, NAC treatment caused the arterial 
pressure to decrease to 4121 mmHg. In addition, 
NAC caused a 91 and 83% reduction in glomerular 
necrosis and tubulo-interstitial nephritis, 
respectively. NAC strengthens the kidney system, 
decreases kidney function disorder and arterial 
blood pressure, and thus, leads to the improvement 
of kidney damage.34 In a study, NAC was not 
effective on blood pressure and surrogated markers 
of cardiovascular injury among non-diabetic 
patients suffering from a chronic kidney disease.14 
Ozaydin et al. concluded that NAC decreased the 
incidence of postoperative atrial fibrillation.35 In the 
research conducted by Krug et al. in Australia, the 
effect of NAC on HTN resulting from 
adrenocorticoids was examined and the results were 
indicative of blood pressure reduction following 
taking NAC. In this study, the effect of NAC on 
HTN resulting from dexametazone usage was 
examined. In their study, 60 patients receiving 
dexametazone received 10 g/l NAC for 4-11 days 
and the patients’ blood pressure reduced. Since 
dexametazone decreases the level of NO in plasma, 
which is a blood vessels tone setter, and increases 
blood pressure, NAC structure decreases the level 
of free radicals due to its antioxidant property, 
elevates the level of NO, and thus, causes the 
relative reduction in blood pressure and in fact its 
setting.36 In their study, Girouard et al. concluded 
that increase in NO-mediated vasodilator tone and 
the possible decrease in adrenergic vasoconstriction 
induced by NAC treatment in SHR could explain 
the hypotensive effect of NAC in this model of 
HTN.14 Meanwhile, in the study by Martina et al.29 
on patients with diabetic nephropathy and HTN, 
the effect of the combination of l-arginine and 
NAC was examined on the level of the patients’ 
blood pressures. Free radicals can decrease NO, so 
it is possible to keep the level of NO unchanged 
through administration of NAC as an antioxidant 
and also l-arginine as an NO setter. In these patients 
with HTN, 1200 mg l-arginine and 600 mg NAC in 
the case group and placebo in the control group 
were prescribed. At the end of the study, the mean 
diastolic and systolic blood pressure in the case 
group decreased.17 The results of several studies are 
consistent with our study results and show that 
NAC is effective in reducing blood pressure. 
Perhaps more noticeable and reliable results were 
obtained by our study than other studies due to our 
study time duration. 
Conclusion 
A patient with HTN with the accurate indications 
and no contradictions for drug usage, especially 
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patients with resistant HTN, can be treated with 
NAC plus ACEIs. 
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